Fluoroquinolone-induced hypoglycemia remains underreported, especially in elderly patients not on any glucose-lowering therapy. Subsequently, healthcare providers may remain unaware of this complication, which can have significant clinical implications in terms of morbidity, mortality, and adverse drug reactions. The authors present the case of an overweight nonagenarian with diabetes, chronic kidney disease, and acute kidney injury who, due to worsening renal function, became hypoglycemic as a result of being unable to efficiently clear fluoroquinolones. The patient was not on any glucose-lowering therapy. Following the case report, the authors provide an overview of the fluoroquinolones approved for use in the United States and discuss their effects on blood glucose levels.